These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 36359760)

  • 21. Frequent expression of complement resistance factors CD46, CD55, and CD59 on gastrointestinal cancer cells limits the therapeutic potential of monoclonal antibody 17-1A.
    Juhl H; Helmig F; Baltzer K; Kalthoff H; Henne-Bruns D; Kremer B
    J Surg Oncol; 1997 Mar; 64(3):222-30. PubMed ID: 9121154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upregulation of Checkpoint Ligand Programmed Death-Ligand 1 in Patients with Paroxysmal Nocturnal Hemoglobinuria Explained by Proximal Complement Activation.
    Anliker M; Drees D; Loacker L; Hafner S; Griesmacher A; Hoermann G; Fux V; Schennach H; Hörtnagl P; Dopler A; Schmidt S; Bellmann-Weiler R; Weiss G; Marx-Hofmann A; Körper S; Höchsmann B; Schrezenmeier H; Schmidt CQ
    J Immunol; 2022 Mar; 208(5):1248-1258. PubMed ID: 35173033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.
    Shao F; Gao Y; Wang W; He H; Xiao L; Geng X; Xia Y; Guo D; Fang J; He J; Lu Z
    Nat Cancer; 2022 Oct; 3(10):1192-1210. PubMed ID: 36271172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection.
    Dammermann W; Schipper P; Ullrich S; Fraedrich K; Schulze Zur Wiesch J; Fründt T; Tiegs G; Lohse A; Lüth S
    PLoS One; 2013; 8(9):e74880. PubMed ID: 24086391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daratumumab: Beyond Multiple Myeloma.
    Ejaz K; Roback JD; Stowell SR; Sullivan HC
    Transfus Med Rev; 2021 Jul; 35(3):36-43. PubMed ID: 34312046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
    van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
    Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
    Xing L; Wang S; Liu J; Yu T; Chen H; Wen K; Li Y; Lin L; Hsieh PA; Cho SF; An G; Qiu L; Kinneer K; Munshi N; Anderson KC; Tai YT
    Clin Cancer Res; 2021 Oct; 27(19):5376-5388. PubMed ID: 34301753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protease-modified erythrocytes: CD55 and CD59 deficient PNH-like cells.
    Yuan FF; Bryant JA; Fletcher A
    Immunol Cell Biol; 1995 Feb; 73(1):66-72. PubMed ID: 7539403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
    Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
    Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of 17-1A antigen and complement resistance factors CD55 and CD59 on liver metastasis in colorectal cancer.
    Hosch SB; Scheunemann P; Lüth M; Inndorf S; Stoecklein NH; Erbersdobler A; Rehders A; Gundlach M; Knoefel WT; Izbicki JR
    J Gastrointest Surg; 2001; 5(6):673-9. PubMed ID: 12086907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
    Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
    Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer.
    Wang G; He L; Wang S; Zhang M; Li Y; Liu Q; Sun N; Zhang X; Liu Y; Zhang J; Tai J; Ni X
    J Clin Endocrinol Metab; 2020 Aug; 105(8):. PubMed ID: 32459310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
    Viola D; Dona A; Caserta E; Troadec E; Besi F; McDonald T; Ghoda L; Gunes EG; Sanchez JF; Khalife J; Martella M; Karanes C; Htut M; Wang X; Rosenzweig M; Chowdhury A; Sborov D; Miles RR; Yazaki PJ; Ebner T; Hofmeister CC; Forman SJ; Rosen ST; Marcucci G; Shively J; Keats JJ; Krishnan A; Pichiorri F
    Leukemia; 2021 Jan; 35(1):189-200. PubMed ID: 32296125
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
    Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
    Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.
    Deng J; Ke H
    Oncoimmunology; 2023; 12(1):2152635. PubMed ID: 36605619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.
    Dzietczenia J; Wróbel T; Mazur G; Poreba R; Jaźwiec B; Kuliczkowski K
    Med Oncol; 2010 Sep; 27(3):743-6. PubMed ID: 19662541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1/PD-L1 in combination with Bortezomib/Immunomodulators plus dexamethasone/prednisone for the treatment of multiple myeloma: an indirect-comparison Meta-analysis of randomised controlled trials.
    Ye W; Wu X; Liu X; Zheng X; Deng J; Gong Y
    BMC Cancer; 2021 Sep; 21(1):994. PubMed ID: 34488679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
    Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.